 People with these mutations are more likely to have adenocarcinoma histology and be non-smokers or light smokers.These people have been shown to be sensitized to certain medications which block the EGFR protein known as tyrosine kinase inhibitors specifically, erlotinib, gefitinib, afatinib or osimertinib.Reliable identification of mutations in lung cancer needs careful consideration due to the variable sensitivity of diagnostic techniques.